Sessa Capital (Master), L.P.
SEC insider (Form 3/4/5 filer). CIK 0001618360. Director at SAB Biotherapeutics, Inc. (SABS). 4 reported Form 4/5 transactions since Sep 2024; latest on Sep 29, 2025. Located in NEW YORK, NY.
Companies Sessa Capital (Master), L.P. has filed insider reports for
- SAB Biotherapeutics, Inc. (SABS): Director
Sessa Capital (Master), L.P.
CIK: 0001618360
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SAB Biotherapeutics, Inc.
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Sep 29, 2025SABS
SAB Biotherapeutics, Inc.
ExerciseDirect1.7M shares at avg. $1.75$3.0M - Jul 22, 2025SABS
SAB Biotherapeutics, Inc.
AwardDirectSeries B Convertible Preferred Stock
228.5K shares- - Jul 22, 2025SABS
SAB Biotherapeutics, Inc.
AwardDirectWarrants (right to buy)
228.5K shares- - Jul 22, 2025SABS
SAB Biotherapeutics, Inc.
AwardDirectWarrants (right to buy)
114.3K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 29, 2025 | SABS SAB Biotherapeutics, Inc. | Exercise | 1,740,000 | $1.75 | $3,045,000 | Direct |
| Jul 22, 2025 | SABS SAB Biotherapeutics, Inc. | Award Series B Convertible Preferred Stock | 228,500 | - | - | Direct |
| Jul 22, 2025 | SABS SAB Biotherapeutics, Inc. | Award Warrants (right to buy) | 228,500 | - | - | Direct |
| Jul 22, 2025 | SABS SAB Biotherapeutics, Inc. | Award Warrants (right to buy) | 114,250 | - | - | Direct |
1-4 of 4 transactions